IAM NASDAQ
Iambic Therapeutics Inc.
1W: -11.8%
YTD: -15.1%
$14.00
-0.41 (-2.85%)
After Hours: $14.05 (+0.05, +0.36%)
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$11.5M
Congress—
ETF Holdings—
Key Statistics
Market Cap$135.1M
52W Range13.02-25
Volume148,908
Avg Volume1,279,547
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOThomas Miller
Employees171
SectorHealthcare
IndustryBiotechnology
IPO Date2026-10-15
Websiteiambic.ai
5627 Oberlin Drive, Suite 120
San Diego, CA 92121
US
San Diego, CA 92121
US
About Iambic Therapeutics Inc.
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Vogelstein R Jacob | C-Conversion | 1,995,749 | — | 2026-10-16 |
| Vogelstein R Jacob | C-Conversion | 1,458,290 | — | 2026-10-16 |
| Vogelstein R Jacob | C-Conversion | 742,546 | $16.00 | 2026-10-16 |
| Vogelstein R Jacob | C-Conversion | 1,141,878 | — | 2026-10-16 |
| Vogelstein R Jacob | C-Conversion | 731,187 | — | 2026-10-16 |